Therapeutic effects of genetically engineered toxin (DAB486IL-2) in patient with chronic lymphocytic leukaemia.
作者信息
LeMaistre C F, Rosenblum M G, Reuben J M, Parkinson D R, Meneghetti C M, Parker K, Shaw J P, Deisseroth A B, Woodworth T
机构信息
Department of Medicine/Hematology, University of Texas Health Science Center, San Antonio 78284-7880.
出版信息
Lancet. 1991 May 11;337(8750):1124-5. doi: 10.1016/0140-6736(91)92788-4.
PMID:1674015
Abstract
In DAB486IL-2 the receptor-binding domain of native diphtheria toxin is replaced by human IL-2 sequences. This recombinant fusion protein is selectively cytotoxic for cells bearing high-affinity IL-2 receptors--eg, leukaemic cells. A patient with chronic lymphocytic leukaemia who did not respond to gamma interferon and conventional antileukaemic drugs has responded to DAB486IL-2.
摘要
Zotero 插件